Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Stage of Development | 9 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Therapy Area | 10 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Indication | 11 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Companies | 14 | 2 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Products under Development by Universities/Institutes | 16 | 2 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Companies Involved in Therapeutics Development | 24 | 7 |
| Akshaya Bio Inc. | 24 | 1 |
| Boehringer Ingelheim GmbH | 25 | 1 |
| Etubics Corporation | 26 | 1 |
| Merck KGaA | 27 | 1 |
| Minerva Biotechnologies Corporation | 28 | 1 |
| Transgene SA | 29 | 1 |
| Vaxil Bio Therapeutics Ltd. | 30 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Drug Profiles | 31 | 28 |
| BI-1361849 Drug Profile | 31 | 2 |
| GO-2032c Drug Profile | 33 | 2 |
| ImMucin Drug Profile | 35 | 4 |
| Monoclonal Antibody to Inhibit MUC1 for Solid Tumors Drug Profile | 39 | 1 |
| tecemotide Drug Profile | 40 | 4 |
| TG-4010 Drug Profile | 44 | 4 |
| Vaccine 1 to Target MUC-1 Protein for Breast Cancer Drug Profile | 48 | 1 |
| Vaccine 2 to Target MUC-1 Protein for Breast Cancer Drug Profile | 49 | 1 |
| Vaccine 3 to Target MUC-1 Protein for Breast Cancer Drug Profile | 50 | 1 |
| Vaccine for Oncology Drug Profile | 51 | 1 |
| Vaccine for Oncology Drug Profile | 52 | 1 |
| Vaccine to Target MUC-1 and TLR-2 for Breast Cancer Drug Profile | 53 | 1 |
| Vaccine to Target MUC1 for Oncology Drug Profile | 54 | 1 |
| Vaccine to Target MUC1 for Oncology Drug Profile | 55 | 1 |
| Vaccine to Target MUC1 for Oncology Drug Profile | 56 | 1 |
| Vaccine to Target MUC1 for Oncology Drug Profile | 57 | 1 |
| Vaccine to Target MUC1 for Oncology Drug Profile | 58 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Dormant Projects | 59 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Discontinued Products | 60 | 1 |
| Mucin 1 (MUC-1 or Breast Carcinoma-Associated Antigen DF3 or Carcinoma-Associated Mucin or CD227) Featured News &Press Releases | 61 | 10 |
| Mar 31, 2016: Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform, Including Its ImMucin Cancer Vaccine | 61 | 1 |
| Dec 23, 2015: Transgene Announces Publication in The Lancet Oncology of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer | 61 | 1 |
| Sep 08, 2015: Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer | 62 | 1 |
| Aug 19, 2015: Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer | 63 | 1 |
| Jun 22, 2015: Vaxil's Lead Product ImMucin has Been Granted an Orphan Drug Designation by the FDA for the Treatment of Multiple Myeloma | 63 | 1 |
| Jun 01, 2015: Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer | 64 | 1 |
| Apr 21, 2015: Transgene Presents New Pre-Clinical Data at AACR on the Combination of TG4010 with Immune Checkpoint Inhibitors | 65 | 1 |
| Mar 16, 2015: VAXIL Receives EU Orphan Drug Designation for ImMucin for the Treatment of Multiple Myeloma | 65 | 1 |
| Jan 21, 2015: NCCS Conducts World s First-In-Human Clinical Trial Of A Novel Cancer Vaccine Targeting Top Cancers In Singapore | 66 | 1 |
| Dec 15, 2014: Vaxil publishes the results of its Phase I/II study using ImMucin in Myeloma Patients in the "British Journal of Hematology" | 67 | 1 |
| Nov 09, 2014: Vaxil has published a review article describing key advantages for its VaxHit technology | 67 | 1 |
| Sep 29, 2014: Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO | 68 | 1 |
| Sep 12, 2014: Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non - Small Cell Lung Cancer | 69 | 1 |
| Aug 18, 2014: Merck Announces Clinical Failure Of Tecemotide Cancer Vaccine | 69 | 1 |
| Aug 12, 2014: MicroVAX Cancer Vaccine First in Human Clinical Trial in Singapore | 70 | 1 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |